Huang Xiaoyu's research while affiliated with Shandong University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
Due to the complexity of pathophysiology of non-small cell lung cancer (NSCLC) and susceptibility of single chemotherapy to drug resistance, the combination of drugs and small interfering RNA (siRNA) may produce desired therapeutic effect on NSCLC through action of multiple pathways. We designed to develop poly-γ-glutamic acid-modified cationic lip...
Citations
... The 3D spheroid experiment results showed that "IND-Lip" nano-conjugate performed noticeably better in ex vivo tumor reduction (Sarvepalli et al. 2022). For the dual delivery of "pemetrexed disodium (PMX) and siRNA" for the treatment of NSCLC, Xiaoyu et al. (2023), created "poly-glutamic acid-modified cationic liposomes (γ-PGA-CL)." The recent research demonstrated the viability of combining "PMX and siRNA via γ-PGA-CL" as a feasible therapy method for NSCLC after in vivo antitumor trials from the complex group significantly inhibited tumor development (Xiaoyu et al. 2023). ...
